ABOUT OUR PARKINSON'S DISEASE PRODUCT

AIP-201: PET Imaging Agent for Parkinson’s Disease (PD)

We've developed a PET imaging agent that allows neurologists the ability to differentiate Parkinson's from essential tremor and other movement disorders.

AIP-201 is a PET imaging agent indicated for striatal dopamine transporter visualization.

PET scans take about 90 minutes

SPECT scans take about 3-6 hours

PET offers sensitivity two to three orders of magnitude higher than SPECT

Fluorine-18, a PET radioisotope, results in one-half the radiation dose of Iodine-123, a SPECT radioisotope

SPECT Scan
PET Scan
PET_edited.png
Screen Shot 2018-08-30 at 6.02.09 PM_edi

69-year-old female patient with essential tremor

 

AIP-201 is not approved by the U.S. Food and Drug Administration and is not marketed in the U.S.

 

A New Drug Application has been submitted to the FDA.